Stay updated with breaking news from Breakthrough Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The American Medical Association’s new coverage and reimbursement codes for FDA-legalized psychedelic-assisted therapies, the current procedural terminology (CPT) III codes, have become active for physicians and other qualified healthcare providers to apply.
Company to present full compliance plan, based on achieving clinical milestones, to Nasdaq on January 4, 2024RADNOR, Pa., Jan. 2, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. , a clinical-stage...
The benefits of ketamine are clear, but so are the risksKetamine has now demonstrated clear superiority to placebo and non-inferiority to electroshock therapy in randomized trials encompassing more...
Tonix recently reported results from second positive Phase 3 trial of Tonmya™ for the management of fibromyalgia In the U.S., New Drug Application (NDA) submission to the FDA planned for the second half of 2024 In Japan, China and most countries in Europe cyclobenzaprine is a New Chemical Entity CHATHAM, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of developme
Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.